<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="529">
  <stage>Registered</stage>
  <submitdate>7/02/2005</submitdate>
  <approvaldate>7/02/2005</approvaldate>
  <nctid>NCT00103168</nctid>
  <trial_identification>
    <studytitle>Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor</studytitle>
    <scientifictitle>Intermediate and High Risk Localized, Completely Resected, Gastrointestinal Stromal Tumors (GIST) Expressing KIT Receptor: A Controlled Randomized Trial on Adjuvant Imatinib Mesylate (Glivec) Versus No Further Therapy After Complete Surgery</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EORTC-62024</secondaryid>
    <secondaryid>EORTC-62024</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastrointestinal Stromal Tumor</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Stomach</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Small bowel (duodenum and ileum)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - imatinib mesylate
Treatment: surgery - adjuvant therapy

Treatment: drugs: imatinib mesylate


Treatment: surgery: adjuvant therapy


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Relapse-free survival</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relapse-free interval</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed gastrointestinal stromal tumor

               -  Localized disease

          -  Meets 1 of the following criteria:

               -  At high-risk of relapse, defined by 1 of the following criteria:

                    -  Tumor size &gt; 10 cm

                    -  Mitotic rate &gt; 10/50 high-power field (HPF)

                    -  Tumor size &gt; 5 cm AND mitotic rate &gt; 5/50 HPF

               -  At intermediate-risk of relapse, defined by 1 of the following criteria:

                    -  Tumor size &lt; 5 cm AND mitotic rate 6-10/50 HPF

                    -  Tumor size 5-10 cm AND mitotic rate &lt; 5/50 HPF

          -  Tumor must stain positive for Kit (CD117) by polyclonal DAKO antibody staining

          -  Must have undergone complete resection of the primary tumor at least 2 weeks, but no
             more than 3 months, before study entry

               -  Meets criteria for 1 of the following resection levels:

                    -  R0 (clear margins)

                    -  R1, defined by 1 of the following criteria:

                         -  Margins of resection are contaminated by tumor, but no macroscopic
                            tumor is left behind

                         -  Intraoperative tumor rupture

                         -  Shelling-out procedure

                         -  Endoscopic maneuver

               -  No residual macroscopic disease after surgery

                    -  Regional positive lymph nodes allowed provided they have been
                       macroscopically excised

          -  No distant metastases*, including any of the following:

               -  Peritoneal lesion not contiguous to the primary tumor

               -  Liver metastases

               -  Hemoperitoneal metastases NOTE: *Even if a complete resection (R0) was performed

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  WHO 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count = 1,500/mm^3

          -  Platelet count = 100,000/mm^3

          -  Hemoglobin = 9 g/dL (transfusions allowed)

        Hepatic

          -  Bilirubin = 1.5 times upper limit of normal (ULN)

          -  AST or ALT = 2.5 times ULN

          -  No uncontrolled liver disease

          -  No chronic viral hepatitis at risk of reactivation

        Renal

          -  Creatinine &lt; 1.5 times ULN

          -  No uncontrolled chronic renal disease

        Cardiovascular

          -  No New York Heart Association class III-IV cardiac disease

          -  No congestive heart failure

          -  No myocardial infarction within the past 2 months

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for up to 3 months after
             study participation

          -  No uncontrolled diabetes

          -  No uncontrolled active infection

          -  No HIV infection

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance or participation

          -  No other severe and/or uncontrolled medical disease

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No other prior molecular targeted or biologic therapy

          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) to support blood counts

          -  No concurrent anticancer biologic agents

        Chemotherapy

          -  No prior chemotherapy for gastrointestinal stromal tumors

          -  No concurrent anticancer chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy

          -  No concurrent anticancer radiotherapy

        Surgery

          -  See Disease Characteristics

          -  Prior non-curative surgery allowed (e.g., surgery with main diagnostic intent or
             emergency surgery with symptomatic intent)

        Other

          -  No prior imatinib mesylate

          -  No prior randomization to this study

          -  No concurrent therapeutic anticoagulation with coumarin derivatives

               -  Concurrent therapeutic low-molecular weight heparin or mini-dose coumarin
                  derivatives (equivalent to oral warfarin 1 mg/day) allowed for prophylaxis of
                  central venous catheter thrombosis

          -  No other concurrent antitumoral therapy

          -  No other concurrent anticancer agents

          -  No other concurrent investigational drugs</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>750</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <postcode>5042 - Bedford Park</postcode>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Herlev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Abbeville</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Besancon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bobigny</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Boulogne Billancourt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Brest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont-Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Colmar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dreux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Chesnay</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Mans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Libourne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Mont-de-Marsan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes-Saint Herblain</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Orleans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Reims</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Cloud</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Priest en Jarez</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre-les-Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tuebingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Scotland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>European Organisation for Research and Treatment of Cancer - EORTC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Italian Sarcoma Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>UNICANCER</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Grupo Espanol de Investigacion en Sarcomas</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth. Giving imatinib mesylate after surgery may kill any remaining
      tumor cells. It is not yet known whether imatinib mesylate is more effective than observation
      only in treating gastrointestinal stromal tumor.

      PURPOSE: This randomized phase III trial is studying imatinib mesylate to see how well it
      works compared to observation only in treating patients who have undergone surgery for
      localized gastrointestinal stromal tumor.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00103168</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paolo G. Casali, MD</name>
      <address>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>